Mark A. Ashwell

1.7k total citations
39 papers, 1.2k citations indexed

About

Mark A. Ashwell is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Mark A. Ashwell has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 17 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Mark A. Ashwell's work include Cancer therapeutics and mechanisms (4 papers), Sulfur-Based Synthesis Techniques (4 papers) and Estrogen and related hormone effects (4 papers). Mark A. Ashwell is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Sulfur-Based Synthesis Techniques (4 papers) and Estrogen and related hormone effects (4 papers). Mark A. Ashwell collaborates with scholars based in United Kingdom, United States and Canada. Mark A. Ashwell's co-authors include Dennis S. France, Richard F. W. Jackson, Chang-Rung Chen, David Leggett, Erika Volckova, Thomas Chan, Neru Munshi, Sébastien Jeay, Magdi Moussa and Jason E. Hill and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Mark A. Ashwell

37 papers receiving 1.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark A. Ashwell 556 423 233 206 144 39 1.2k
Steven F. Bellon 1.1k 2.1× 373 0.9× 165 0.7× 496 2.4× 45 0.3× 21 1.6k
Alfred P. Spada 664 1.2× 789 1.9× 195 0.8× 172 0.8× 38 0.3× 44 1.8k
Joseph Schoepfer 1.5k 2.8× 532 1.3× 102 0.4× 470 2.3× 149 1.0× 43 2.0k
Yoshio Koide 311 0.6× 383 0.9× 77 0.3× 192 0.9× 223 1.5× 52 1.2k
John W. Ellingboe 893 1.6× 906 2.1× 115 0.5× 122 0.6× 36 0.3× 54 1.8k
Ariamala Gopalsamy 730 1.3× 896 2.1× 119 0.5× 125 0.6× 29 0.2× 54 1.5k
Jay P. Powers 455 0.8× 333 0.8× 83 0.4× 400 1.9× 267 1.9× 66 1.7k
Ursula Müller‐Vieira 454 0.8× 225 0.5× 263 1.1× 112 0.5× 80 0.6× 29 1.5k
Ulrich Grädler 616 1.1× 180 0.4× 81 0.3× 125 0.6× 80 0.6× 28 987
Cristina Lewis 935 1.7× 219 0.5× 190 0.8× 319 1.5× 49 0.3× 26 1.4k

Countries citing papers authored by Mark A. Ashwell

Since Specialization
Citations

This map shows the geographic impact of Mark A. Ashwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Ashwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Ashwell more than expected).

Fields of papers citing papers by Mark A. Ashwell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Ashwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Ashwell. The network helps show where Mark A. Ashwell may publish in the future.

Co-authorship network of co-authors of Mark A. Ashwell

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Ashwell. A scholar is included among the top collaborators of Mark A. Ashwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Ashwell. Mark A. Ashwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Murai, Takahiro, Hideo Takakusa, Daisuke Nakai, et al.. (2014). Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica. 44(11). 996–1008. 11 indexed citations
2.
Eathiraj, Sudharshan, Rocio Palma, Erika Volckova, et al.. (2011). Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197. Journal of Biological Chemistry. 286(23). 20666–20676. 118 indexed citations
3.
Eathiraj, Sudharshan, Rocio Palma, Marscha Hirschi, et al.. (2011). A Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases. Journal of Biological Chemistry. 286(23). 20677–20687. 47 indexed citations
4.
Chan, Thomas, Jean‐Marc Lapierre, Mark A. Ashwell, et al.. (2011). Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.. Molecular Cancer Therapeutics. 10(11_Supplement). A230–A230. 3 indexed citations
5.
Munshi, Neru, Sébastien Jeay, Youzhi Li, et al.. (2010). ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity. Molecular Cancer Therapeutics. 9(6). 1544–1553. 274 indexed citations
6.
Miao, Xiu‐Sheng, Ronald E. Savage, Caiyun Zhong, et al.. (2008). Identification of the in Vitro Metabolites of 3,4-Dihydro-2,2-dimethyl-2H-naphthol[1,2-b ]pyran-5,6-dione (ARQ 501; β-Lapachone) in Whole Blood. Drug Metabolism and Disposition. 36(4). 641–648. 25 indexed citations
7.
Miao, Xiu‐Sheng, Caiyun Zhong, Yunxia Wang, et al.. (2008). In vitro metabolism of β ‐lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Communications in Mass Spectrometry. 23(1). 12–22. 19 indexed citations
8.
Zhang, Bin, et al.. (2008). High-Content Fluorescent-Based Assay for Screening Activators of DNA Damage Checkpoint Pathways. SLAS DISCOVERY. 13(6). 538–543. 11 indexed citations
9.
Yang, Rui‐Yang, Darin Kizer, Hui Wu, et al.. (2008). Synthetic methods for the preparation of ARQ 501 (β-Lapachone) human blood metabolites. Bioorganic & Medicinal Chemistry. 16(10). 5635–5643. 51 indexed citations
10.
Jeay, Sébastien, Neru Munshi, Jason E. Hill, et al.. (2007). ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. Cancer Research. 67. 2369–2369. 17 indexed citations
11.
Steffan, Robert J., Edward Matelan, Mark A. Ashwell, et al.. (2006). Control of Chronic Inflammation with Pathway Selective Estrogen Receptor Ligands. Current Topics in Medicinal Chemistry. 6(2). 103–111. 11 indexed citations
12.
Wilson, Christopher J., Ying Si, Andrew Smellie, et al.. (2006). Identification of a Small Molecule That Induces Mitotic Arrest Using a Simplified High-Content Screening Assay and Data Analysis Method. SLAS DISCOVERY. 11(1). 21–28. 29 indexed citations
13.
Ashwell, Mark A., et al.. (2005). Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorganic & Medicinal Chemistry Letters. 16(4). 854–858. 5 indexed citations
14.
Ashwell, Mark A., et al.. (2004). The design, preparation and SAR of novel small molecule sodium (Na + ) channel blockers. Bioorganic & Medicinal Chemistry Letters. 14(9). 2025–2030. 2 indexed citations
15.
Tandon, Manish, et al.. (2004). The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorganic & Medicinal Chemistry Letters. 14(7). 1709–1712. 23 indexed citations
16.
Tandon, Manish, David L. Coffen, Paul Gallant, Dennis D. Keith, & Mark A. Ashwell. (2004). Potent and selective inhibitors of bacterial methionyl tRNA synthetase derived from an oxazolone–dipeptide scaffold. Bioorganic & Medicinal Chemistry Letters. 14(8). 1909–1911. 25 indexed citations
17.
Steffan, Robert J., et al.. (2002). Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 2: Arylethanolaminomethylpiperidines. Bioorganic & Medicinal Chemistry Letters. 12(20). 2963–2967. 8 indexed citations
18.
Steffan, Robert J., et al.. (2002). Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 1: aryloxypropanolaminomethylpiperidines. Bioorganic & Medicinal Chemistry Letters. 12(20). 2957–2961. 8 indexed citations
19.
Ashwell, Mark A., et al.. (2001). 4-Aminopiperidine ureas as potent selective agonists of the human β3-Adrenergic receptor. Bioorganic & Medicinal Chemistry Letters. 11(24). 3123–3127. 14 indexed citations
20.
Ashwell, Mark A., et al.. (2000). The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery. Bioorganic & Medicinal Chemistry Letters. 10(8). 783–786. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven F. Bellon Breakdown of academic impact, for papers by Alfred P. Spada Breakdown of academic impact, for papers by Joseph Schoepfer Breakdown of academic impact, for papers by Yoshio Koide Breakdown of academic impact, for papers by John W. Ellingboe Breakdown of academic impact, for papers by Ariamala Gopalsamy Breakdown of academic impact, for papers by Jay P. Powers Breakdown of academic impact, for papers by Ursula Müller‐Vieira Breakdown of academic impact, for papers by Ulrich Grädler Breakdown of academic impact, for papers by Cristina Lewis
Rankless by CCL
2026